Director/Senior Director, EMEA Health Economics and Outcomes Research (HEOR) Leader
- Location
- Zug
- Workplace
- Hybrid
- Employment
- Full-time
About this role
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need.
As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Summary of Position:
The Director/Senior Director, EMEA Health Economics and Outcomes Research (HEOR) Leader, reporting to the Vice President Global Medical Affairs, will lead the development and execution of the go-to market strategy and deliverables to support value of apitegromab as well as the clinical stage Scholar Rock portfolio, in close partnership with the cross-functional matrix team.
This individual will serve as the strategic leader and subject matter expert for EMEA HEOR, responsible for country-level budget impact and cost-effectiveness model adaptations, evidence generation plans, and value communications required to support the national health technology assessment (HTA), payer dossiers, EU Joint Clinical Assessment (JCA), and reimbursement negotiations of Scholar Rock treatments. The role requires strong strategic leadership and cross-functional collaboration with Medical Affairs, Market Access, Commercial, Clinical Development and the regional teams in EMEA to optimize access and reimbursement for patients worldwide.
The successful candidate will develop strategic partnerships and research collaborations with external experts, healthcare policymakers, payers and various academic centers to support the strategy for apitegromab and future products.
\nPosition Responsibilities- Develop HEOR strategies for EMEA, with an emphasis on Europe, that support product value demonstration, reimbursement, market access, and launch objectives.
- Lead the design, implementation, and oversight of HEOR studies, models, and deliverables for Europe.
- Collaborate with Medical, Market Access, and Biostatistics to determine real-world evidence needs for payers in Europe—including registries, natural history and external control analyses, burden of illness, treatment patterns, resource use, and addressing evidence requirements arising in HTA appraisal and reimbursement negotiations.
- Incorporate evidence gaps needed for European payers into evidence generation plans
- Direct evidence synthesis and value communication for payer and HTA bodies.
- Serve as Europe HEOR partner to Europe Market Access for access and reimbursement dossiers by providing country-specific adaptations of models, methodology guidance, and scientific reviews that support country-level deliverables.
- Own the HEOR deliverables for timely submissions to EU JCA, including PICO-driven evidence planning and comparative effectiveness analyses.
- Work closely across Global HEOR and cross-functional teams to inform endpoint, patient-reported outcome, and utility data collection strategy for clinical development programs so that trials generate evidence acceptable to payers and HTA bodies.
- Manage external HEOR vendors, budgets, and contracts, ensuring quality and timely delivery across competing priorities.
- Translate complex HEOR outputs and requirements into plain-language value narratives for internal leadership and external payers.
- Graduate degree in health economics, epidemiology, health services research, or another research-focused public health discipline
- 8+ years of HEOR experience with an MSc/MPH, or 5+ years with a PhD
- Extensive experience leading HEOR evidence generation to support HTA submissions across multiple markets in Europe
- Direct experience engaging with HTA organizations in Europe
- Working knowledge of EU HTA regulations and Joint Clinical Assessment process
- Experience developing or adapting budget-impact and cost-effectiveness models
- Experience conducted indirect treatment comparisons or network meta-analysis
- Strong track record of managing vendors
- Ability to influence cross-functional and regional stakeholders without direct authority
- Excellent written and verbal communication skills
- Prior experience in neuromuscular disease and/or rare diseases is preferred but not required.
- ~15% travel, ability to work across global time zones
Scholar Rock is an Equal Opportunity Employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
Apply to Scholar Rock
Clera fills in Scholar Rock's application for you.
How it works
Open the role in Clera
Sign in, and this role opens on your Clera job board, ready to apply.
Clera fills in the application
Clera fills the form from your profile and resume, and asks what's missing.
Track it in Clera
Each application you send shows up in your Clera tracker, sorted by stage.
Ask your AI about this role
It knows you. Clera gives it the role.
First time? Connect Clera once, about a minute.
https://mcp.getclera.comSign in with your Clera account. MCP docs
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X.
For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/
For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
- Team size
- 51-200 employees people
- Founded
- 2012
- Industry
- Biotechnology
- Workplace
- Hybrid